Peanut Allergy Articles & Analysis
20 news found
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology ...
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut ...
The initial two product candidates for human medicine are vaccines against cat allergy and peanut allergy, the first of which will enter clinical development in the second half of 2022. Besides their allergy program, ANGANY is also working in developing other immunotherapy applications including degenerative disease and oncology ...
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory. ...
Food Allergy Research and Education (FARE) has established that more than 32 million people in the US are victims of food allergy. ...
In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes including pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), chronic obstructive pulmonary disease with evidence of type 2 inflammation (Phase 3), eosinophilic esophagitis (Phase 3), bullous pemphigoid ...
In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including eosinophilic esophagitis (Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), chronic rhinosinusitis without nasal polyposis (Phase 3), chronic obstructive pulmonary disease with ...
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has ...
NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy. ...
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the promotion of Sergi Trilla, MD to become Director of Corporate Strategy & Partnerships. ...
“Angany’s approach should bring hope to the millions of people affected by respiratory and food allergy. We are looking forward to communicating with US allergists on how this innovative form of allergy immunotherapy may soon help them provide better options for people faced with allergy,” states Dr. ...
“Supporting peanut allergy patients and their loved ones has always been the central mission at Intrommune,” said Michael Nelson, CEO of Intrommune Therapeutics. ...
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. ...
Angany’s goal: help people with allergies get their life back. Leveraging over 30 years of research in biotechnology, immunology and vaccinology, and after more than $ 15M of R&D investments, ANGANY has tackled the specific challenges of allergy to invent a new generation of pharmaceutical products. ...
Hans van Schijndel has a PhD in Biochemistry and is employed by HAL Allergy since 2012. In his career at HAL Allergy he served as Principal Scientist/Head of Pre-clinical Research and was engaged in several bio-technological projects including the Therapieallergene-Verordnung (TAV) program. In his position of Chief R&D Officer he will take care of this ...
OMIT enables regular administration of allergy immunotherapy to desensitize a patient to allergies while a user brushes their teeth. ...
Addressing critical health concerns, PB’s patented technology is currently in clinical studies, collaborations and partnerships addressing complex neurological diseases, such as Autism, Parkinson’s and Alzheimer’s, in addition to other common conditions having a genetic component such as endometriosis and peanut allergy. ...
OMIT enables regular administration of allergy immunotherapy while a user brushes their teeth. Allovate retains the global rights to develop products based on the OMIT platform for the treatment of respiratory allergies. Allovate is licensing the rights to develop the OMIT platform for the treatment of food allergies to Intrommune Therapeutics, ...
Sweet lupin protein, fiber, and flour: A company determined as safe for use in baked goods, dairy products, gelatin, meats, and candy, despite FDA-raised questions about whether or not the chemicals would cause serious allergic reactions in those with peanut allergies. Theobromine: A company determined as safe for use in bread, cereal, beverages, chewing gum, ...
The research, which was funded by the National Institutes of Health and appears in the Journal of Allergy and Clinical Immunology, is the first to use a nationally representative sample, as well as specific immunoglobulin E (IgE) or antibody levels to quantify allergic sensitization to common foods, including peanuts, milk, eggs, and shrimp. ...